Resolution of the Research Council of Experts on the place of netakimab, a new interleukin-17a inhibitor, in the therapy of ankylosing spondylitis
.
Main Author: | article Editorial |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2020-06-01
|
Series: | Научно-практическая ревматология |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2906 |
Similar Items
-
Resolution of the Scientific Council of Experts: “The place of netakimab, a new inhibitor of IL-17A, in the treatment of psoriatic arthritis
by: article Editorial
Published: (2020-09-01) -
Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2022-12-01) -
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01) -
Interleukin-1 and susceptibility to ankylosing spondylitis
by: Edwards, S, et al.
Published: (2001) -
Interleukin 10 polymorphisms in ankylosing spondylitis.
by: Goedecke, V, et al.
Published: (2003)